Robert Michael Dudley - 09 Jun 2023 Form 4/A - Amendment Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol: RNAZ
Transactions as of: 09 Jun 2023
Net transactions value: +$52,440
Form type: 4/A - Amendment
Filing time: 14 Jun 2023, 16:16:17 UTC
Date Of Original Report: 13 Jun 2023
Previous filing: 19 May 2023
Next filing: 22 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNAZ	Common Stock	Purchase	$52,440	+19,000	+45%	$2.76	61,155	09 Jun 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
F2	This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023.

Content

Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023.